Globes business newspaper is reporting that Nervomatrix out of Netanya, Israel has received FDA regulatory approval for its Auto-Targeting Neurostimulation (ATN) system. ATN delivers a more precisely focused electric current than traditional external neurostimulation by sensing areas of varying electrical resistance.
Nervomatrix’s patent is for a back scanner and nerve ending locator which takes into account their relative electrical resistance compared with the surrounding area. “We found that when pain lessens, the electrical tension at different points equalizes,” said Kanner. “In future, it may be possible to use this data to monitor the progress of treatment. We will be able to examine whether a person is actually suffering pain, which is important for preventing insurance fraud.”
Nervomatrix carried out it first trial at Bnei Zion Hospital in Haifa. 85% of patients reported improvement in their condition, but there was no control group. The company’s next stage is to conduct a clinical trial at New York University even as it begin treating patients with its products at two medical centers in New York.